{"sponsor":"Bristol Myers Squibb","url":"https://www.bmspaf.org/#/eligibility","readDate":"2026-10-29","method":"chrome get_page_text","facts":{"incomeRule":"dollars","dollars1":47880,"dollars2":64920,"appliesTo":"Eliquis and Orencia; larger families adjusted","exemptFromIncomeLimit":"BMS medicines for cancer, ulcerative colitis, multiple sclerosis, plaque psoriasis, obstructive hypertrophic cardiomyopathy, kidney transplant","insurance":"no coverage for the medicine, or Medicare with at least 3% of yearly household income spent on out-of-pocket prescriptions in the same calendar year","medicare":"allowed-with-conditions: age 65+ must not qualify for Part D LIS (proof of denial); 3% spend rule","other":"Medicaid-eligible must submit proof of Medicaid denial; US or territory resident; US licensed prescriber; outpatient"}}
{"sponsor":"Bristol Myers Squibb","url":"https://www.bmspaf.org/#/medicines","readDate":"2026-10-29","method":"chrome get_page_text","facts":{"listedDrugs":["Abraxane","Augtyro","Camzyos","Cobenfy","Eliquis","Empliciti","Idhifa","Inrebic","Istodax","Krazati","Nulojix","Onureg","Opdivo","Opdivo Qvantig","Opdualag","Orencia","Pomalyst","Reblozyl","Revlimid","Sotyktu","Sprycel","Thalomid","Vidaza","Yervoy","Zenbexus","Zeposia"]}}
{"sponsor":"AstraZeneca","url":"https://www.azandmeapp.com/eligibility-requirements","readDate":"2026-10-29","method":"chrome get_page_text","facts":{"incomeRule":"fpl-pct","fplPct":300,"rareDiseasePct":500,"rareDiseaseDrug":"Wainua","incomeBasis":"annual adjusted gross income","insurance":"no commercial or government insurance other than Medicare","medicare":"allowed-with-conditions: must not be eligible for or enrolled in Part D Extra Help (LIS)","other":"under 150% FPL may need Medicaid or LIS denial letter; not receiving other medication assistance","trademarkLineNamesFarxiga":false}}
{"sponsor":"Novo Nordisk","url":"https://www.novocare.com/diabetes/help-with-costs/pap.html","readDate":"2026-10-29","method":"chrome get_page_text","sha256_expanded":"33ba24c62fbd4d3661f730bbc711b5bd09b09e3222cef1500d86db399b94a931","facts":{"incomeRule":"states only 'a total household income that qualifies' and refers to NeedyMeds for FPL; no percentage seen in visible text","insurance":"Medicare or no insurance; private or commercial insurance is not eligible","medicare":"allowed-with-conditions: must submit LIS denial letter if LIS-eligible; Part D enrollees may apply for next year after 2026-10-15","other":"must not be enrolled in or qualify for Medicaid, LIS or VA benefits; US citizen or legal resident"}}
{"sponsor":"Novo Nordisk","url":"https://www.novocare.com/content/dam/novonordisk/novocare/forms/PAP_Product_List.pdf","readDate":"2026-10-29","method":"chrome screenshot of PDF (form code NNIPAP_11_01012026)","facts":{"listedDrugs":["Ozempic","Xultophy 100/3.6","Fiasp","Novolin R","Novolin N","Novolin 70/30","NovoLog","NovoLog Mix 70/30","Tresiba"],"uninsuredOnly":["Ozempic","Xultophy 100/3.6","FlexPen/FlexTouch/PenFill presentations marked with asterisk-style symbol; footnote 'Available for uninsured patients ONLY' attaches to the dagger on Ozempic and Xultophy"],"notListed":["Wegovy","Rybelsus","Victoza"]}}
{"sponsor":"Novo Nordisk","url":"https://www.novocare.com/content/dam/novonordisk/novocare/forms/PAP_Application_EN.pdf","readDate":"2026-10-29","method":"chrome screenshot of PDF pages 1 and 2 (form code NNIPAP_14_Oct2025)","facts":{"incomeFigure":"none on pages 1-2; form asks household size and says income is electronically verified; no percentage or dollar limit published on the sponsor page, product list or form page 1"}}
{"sponsor":"AstraZeneca","url":"https://www.azandmeapp.com/important-program-updates","readDate":"2026-10-29","method":"chrome expanded accordion, screenshot","facts":{"drug":"Farxiga and Xigduo XR","status":"removed from AZ&Me for new patients effective 2026-05-01; enrolled patients supported until 2026-12-31; reason stated: generic equivalents available since April 2026","addedProducts":["Baxfendy","Etcamah"],"incomeRule2027":"AZ&Me states income eligibility requirements remain the same for 2027"}}
{"sponsor":"GSK","url":"https://gskpaf.org/gsk/prescription-medicine-patient-assistance/","readDate":"2026-10-29","method":"chrome page text","sha256":"af1679e881beaf575adc5a2bab0c8a6d62d0fbd19474a5c199bd962b934e7744","facts":{"incomeRule":"states 'meet financial income eligibility criteria'; no figure on this page","insurance":"uninsured OR Medicare with other program requirements","other":"US or Puerto Rico resident; US licensed provider; patients in an Alternate Funding Program not eligible; product list is a separate link (not yet read)"}}
{"sponsor":"Pfizer","url":"https://www.pfizerrxpathways.com/updates","readDate":"2026-10-29","method":"chrome page text, keyword extraction truncated","sha256":"64a98a8135303dcdf304ba39e9961bf7e21fb215564dbb909f631ec87837a164","facts":{"medicare":"allowed-with-conditions: Medicare Prescription Payment Plan enrollment attestation required; proof of MPPP enrollment required above 138% FPL; Part D out-of-pocket maximum stated as $2,100 for most Part D / Advantage patients"}}
{"sponsor":"GSK","url":"https://gskpaf.org/gsk/prescription-medicine-patient-assistance/medicare/","readDate":"2026-10-29","method":"chrome page text","sha256":"d342140bea319fd0f025ba3ad5841ce0ff77388ab9bea1c101e6bb4af4f6a064","facts":{"path":"Medicare Part D patients","incomeRule":"dollars","table":{"48 states and DC":[47880,64920,81960,99000,17040],"Alaska":[59850,81150,102450,123750,21300],"Hawaii":[55080,74670,94260,113850,19590],"Puerto Rico":[28800,36000,43200,50400,7200]},"tableColumns":"household of 1,2,3,4 then each additional person","insurance":"Medicare prescription drug plan","medicare":"allowed-with-conditions: must have paid a total of $600 for prescriptions in the current calendar year","other":"US or Puerto Rico resident; not eligible for Mi Salud or denied"}}
{"sponsor":"Pfizer","url":"https://www.pfizerrxpathways.com/updates","readDate":"2026-10-29","method":"chrome page text","facts":{"incomeRule":"fpl-pct","fplPct":300,"incomeBasis":"annual pre-tax household income","insurance":"uninsured or government insured and unable to afford their copayment","history":"2024 changes removed eligibility for 301 to 500 percent FPL patients; page text describes earlier transition for previously enrolled patients"}}
{"sponsor":"Boehringer Ingelheim","url":"https://www.boehringer-ingelheim.com/us/about-us/sustainable-development/our-commitment/pdf/pap-important-updates","readDate":"2026-10-29","method":"chrome screenshot of PDF (5 pages, pages 1-2 read so far)","facts":{"medicareChange":"As of 2026-10-15 the Boehringer Cares PAP no longer accepts new enrollments from people with Medicare Part D or Medicare Advantage drug coverage for its primary care products, including Combivent Respimat, Glyxambi, Jardiance, Jentadueto, Jentadueto XR, Spiriva Respimat, Stiolto Respimat, Synjardy, Synjardy XR, Tradjenta (list continues on page 3, not yet read)","removed":{"Ofev":"no longer available as of 2026-09-11; enrolled patients continue to end of enrollment period or 2027-12-31","Aptivus, Atrovent, Striverdi":"no new enrollments as of 2026-10-15; enrolled continue to 2026-12-31 (Aptivus while available)"}}}
{"sponsor":"Lilly","url":"https://www.lillycares.com/how-to-apply","readDate":"2026-10-29","method":"chrome get_page_text","facts":{"incomeRule":"fpl-pct by medicine group, stated as 300% / 400% / 500% of 2026 Federal Poverty Guidelines","groups":{"1":{"fplPct":300,"dollars":[47880,64920,81960,99000,116040,133080],"drugs":["Cialis","Emgality","Forteo","Reyvow","Trulicity"],"insurance":"no insurance or Medicare Part D"},"2":{"fplPct":400,"dollars":[63840,86560,109280,132000,154720,177440],"drugs":["Basaglar","Humalog","Humulin","Lyumjev"],"insurance":"no insurance or Medicare Part D"},"3":{"fplPct":500,"dollars":[79800,108200,136600,165000,193400,221800],"drugs":["Ebglyss","Olumiant","Omvoh infusion","Omvoh injection","Taltz"],"insurance":"no insurance, Part D (not infused), or Part B without supplemental"},"4":{"fplPct":500,"drugs":["Cyramza","Erbitux","Inluriyo","Jaypirca","Kisunla","Retevmo","Verzenio"],"insurance":"no insurance, Part D (not infused), or Part B without supplemental"}},"alaskaHawaii":"contact the program for limits","exclusions":"Medicaid, full LIS (Extra Help), VA benefits; alternative funding programs","note":"Trulicity applications again accepted and no longer need a medical exception request (banner)"}}
{"sponsor":"Lilly","url":"https://www.lillycares.com/available-medications","readDate":"2026-10-29","method":"chrome get_page_text","facts":{"mounjaroListed":false,"zepboundListed":false,"trulicityListed":true,"humalogListed":true}}
{"sponsor":"Amgen","url":"https://www.amgensafetynetfoundation.com/eligibility.html","readDate":"2026-10-29","method":"chrome page text","sha256":"f6fc0a1125762f5c0bdc9a121ac31de96626d642e37873e5972ddc3c440b7bf2","facts":{"incomeRule":"states 'income guidelines vary by product'; no figure on this page","insurance":"no insurance coverage; for certain products Medicare patients with an affordability gap and no alternative support (Extra Help or independent copay foundation)"}}
{"sponsor":"Merck","url":"https://www.merckhelps.com/KEYTRUDA","readDate":"2026-10-29","method":"chrome get_page_text","facts":{"drug":"Keytruda","incomeRule":"dollars","dollars1":79800,"dollars2":108200,"dollars4":165000,"insurance":"uninsured: no private insurance, HMO, Medicaid, Medicare, state pharmacy assistance or VA coverage; exception possible with attested financial and medical hardship if income meets criteria","medicare":"excluded (Medicare listed as other coverage), exception route for hardship","alaskaHawaii":"call 1-800-727-5400","other":"alternative funding program participants ineligible; US legal residents incl. territories"}}
{"sponsor":"Sanofi","url":"https://www.sanofipatientconnection.com/financial-eligibility","readDate":"2026-10-29","method":"chrome get_page_text","facts":{"incomeRule":"fpl-pct","fplPct":400,"table48States":{"guideline":[15960,21640,27320,33000,38680,44360,50040,55720],"limit400":[63840,86560,109280,132000,154720,177440,200160,222880],"perExtraGuideline":5680},"tableAlaska":{"guideline1":19950,"limit1":79800,"perExtraGuideline":6880},"tableHawaii":{"guideline1":18360,"limit1":73440,"perExtraGuideline":7100},"applies":"Patient Assistance Connection for uninsured or functionally uninsured patients","guidelineSource":"HHS, accessed 01/20/2026 per Sanofi page"}}
{"sponsor":"Merck","url":"https://www.merckhelps.com/JANUVIA","readDate":"2026-10-29","method":"chrome page text","facts":{"drug":"Januvia","incomeRule":"dollars","dollars1":63840,"dollars2":86560,"dollars4":132000}}
{"sponsor":"Sanofi","url":"https://www.sanofipatientconnection.com/medications-available","readDate":"2026-10-29","method":"chrome get_page_text","facts":{"listedDrugs":["Adacel","Admelog","Apidra","Elitek","Imovax Rabies","Jevtana","Lantus","Lovenox","MenQuadfi","Merilog","Mozobil","Multaq","Pentacel","Priftin","Soliqua","Synvisc-One","Synvisc","Tenivac","Thymoglobulin","Thyrogen","Toujeo"],"notListed":["Dupixent","Kevzara","Praluent","Aubagio","Sarclisa"]}}
{"sponsor":"Johnson & Johnson","url":"https://asset.jnjwithme.com/document/JnJ_Patient_Assistance_Quick_Reference_Guide_Other_Medications.pdf","readDate":"2026-10-29","method":"chrome screenshot of PDF pages 1-2","facts":{"incomeRule":"fpl-pct","fplPct":300,"table2026ProgramLimit":{"allExceptAKHI":[46950,63450,79950,96450,112950,129450,145950],"perExtra":16500,"Alaska":[58650,79290,99930,120570,141210,161850,182490],"AlaskaPerExtra":20640,"Hawaii":[53970,72960,91950,110940,129930,148920,167910],"HawaiiPerExtra":18990},"note":"the guide labels this '2026 Program Income Limit' while the one-person figure equals 300% of $15,650, the 2025 guideline; 300% of the 2026 guideline would be $47,880","insurance":"uninsured or inadequate commercial, employer or government coverage including Medicare, Medicaid, TRICARE, VA","medicare":"allowed-with-conditions: Part D patients must show they are not eligible for LIS (requirement applies when income is at or below 150% FPL)","listedDrugsSample":["Akeega","Balversa","Caplyta","Darzalex","Darzalex Faspro","Edurant","Elmiron","Erleada","Inlexzo","Intelence","Invega Hafyera","Invega Sustenna","Invega Trinza","Invokamet","Invokana","Prezcobix","Prezista","Risperdal Consta","Rybrevant","Sirturo","Spravato","Symtuza","Talvey","Tecvayli","Xarelto","Yondelis"],"notOnThisGuide":["Stelara","Tremfya","Imbruvica"]}}
{"sponsor":"Novartis","url":"https://pap.novartis.com/","readDate":"2026-10-29","method":"chrome get_page_text","facts":{"incomeRule":"states 'meet income guidelines' with different Alaska and Hawaii limits; no figure on the page (the figure sits behind an interactive eligibility tool, not used)","insurance":"uninsured or government insurance; Extra Help denial evidence may be required","other":"US or territory resident; outpatient; alternate funding program patients excluded"}}
{"sponsor":"Novartis","url":"https://pap.novartis.com/medications-list/","readDate":"2026-10-29","method":"chrome page text","facts":{"entrestoListed":false,"listedSample":["Adakveo","Beovu","Cosentyx","Fabhalta","Ilaris","Kesimpta","Kisqali","Leqvio","Mayzent","Pluvicto","Scemblix","Tafinlar","Vijoice"],"note":"list truncated at 1270 characters of page text after 'Contact', Entresto absent from the full text of the list"}}
{"sponsor":"AbbVie","url":"https://www.abbvie.com/patients/patient-support/patient-assistance.html","readDate":"2026-10-29","method":"chrome get_page_text","facts":{"incomeRule":"no figure on this page; an 'Income criteria' topic link exists (not yet read)","insurance":"no or limited insurance coverage and demonstrated financial need","returningPatientMedicines":["Creon","Decnupaz","Elahere","Emrelis","Linzess","Mavyret","Qulipta","Rinvoq","Skyrizi","Ubrelvy","Viberzi","Vraylar"],"humiraOnThisPage":false}}
{"sponsor":"GSK","url":"https://gskpaf.org/gsk/prescription-medicine-patient-assistance/","readDate":"2026-10-29","method":"chrome, program's own medicine lookup box (read-only search, no personal data)","facts":{"listed":["Trelegy Ellipta","Anoro Ellipta","Breo Ellipta"],"note":"income figure for the non-Medicare (uninsured) path not located; only the Medicare path table was read"}}
{"sponsor":"Amgen","url":"https://www.amgensafetynetfoundation.com/assets/pdf/AMGEN-SNF-Application-Prescription-Repatha-EN.pdf","readDate":"2026-10-29","method":"chrome screenshot of PDF page 1","facts":{"drug":"Repatha","incomeRule":"dollars","dollars1":47880,"dollars2":64920,"perExtraPerson":17040,"insurance":"no insurance coverage","medicare":"excluded on this application's stated requirements (no insurance coverage); the eligibility page notes certain products allow Medicare patients with an affordability gap","other":"lived in US, American Samoa, Guam, Puerto Rico or USVI six months or longer; prescriptions submitted electronically by the prescriber"}}
{"sponsor":"Amgen","url":"https://www.amgensafetynetfoundation.com/assets/pdf/AMGEN-SNF-Application-Prescription-Otezla-EN.pdf","readDate":"2026-10-29","method":"chrome screenshot zoom of PDF page 1","facts":{"drug":"Otezla","incomeRule":"dollars","dollars1":47880,"dollars2":64920,"perExtraPerson":17040,"insurance":"no insurance coverage"}}
{"sponsor":"Amgen","url":"https://www.amgensafetynetfoundation.com/assets/pdf/AMGEN-SNF-Application-Prescription-Enbrel-EN.pdf","readDate":"2026-10-29","method":"chrome screenshot zoom of PDF page 1","facts":{"drug":"Enbrel","incomeRule":"dollars","dollars1":47880,"dollars2":64920,"perExtraPerson":17040,"insurance":"no insurance coverage"}}
{"sponsor":"Boehringer Ingelheim","url":"https://www.boehringer-ingelheim.com/us/about-us/sustainable-development/our-commitment/pdf/patient-assistance-program-eligibility-information","readDate":"2026-10-29","method":"chrome screenshot of PDF pages 1-3 (document code NP-US-100242, dated 09/2026)","facts":{"incomeRule":"fpl-pct","respimatGroup":{"drugs":["Combivent Respimat","Spiriva Respimat","Stiolto Respimat"],"fplPct":200,"limits48States":[31920,43280,54640,66000,77360,88720],"limitsAlaska":[39900,54100,68300,82500,96700,110900],"limitsHawaii":[36720,49780,62840,75900,88960,102020]},"allOtherGroup":{"drugsInInsuranceTable":["Glyxambi","Jardiance","Jentadueto","Jentadueto XR","Synjardy","Synjardy XR","Tradjenta","Trijardy XR","Gilotrif","Hernexeos","Jascayd"],"fplPct":250,"limits48States":[39900,54100,68300,82500,96700,110900],"limitsAlaska":[49875,67625,83375,103125,120875,138625],"limitsHawaii":[45900,62225,78550,94875,111200,127525],"inference":"Jardiance and Tradjenta fall under 'all other medications listed below' because they are not in the Respimat heading"},"insuranceTable":{"primaryCare":{"uninsured":"eligible","medicarePartD":"not eligible","insuredCovered":"not eligible"},"specialtyCare":{"uninsured":"eligible","medicarePartD":"eligible","insuredCovered":"not eligible"}},"medicareChange":"effective 2026-10-15 no new patient enrollments for Medicare Part D or Advantage on primary care products","householdDefinition":"applicant plus spouse and children under 19 living with them"}}
{"sponsor":"AbbVie","url":"https://www.abbvie.com/patients/patient-support/patient-assistance/income-criteria.html","readDate":"2026-10-29","method":"chrome get_page_text","facts":{"incomeRule":"dollars","dollars":[63840,86560,109280,132000],"perExtraAfter4":22720,"insurance":"limited or no health insurance; with insurance, financial need is reviewed from coverage, income and out-of-pocket expenses","other":"alternate funding program patients excluded"}}
{"sponsor":"HHS ASPE","url":"https://aspe.hhs.gov/topics/poverty-economic-mobility/poverty-guidelines","readDate":"2026-10-29","method":"chrome page text","facts":{"guideline2026_48statesDC":{"persons":[15960,21640,27320,33000,38680,44360,50040,55720],"perExtraAfter8":5680},"guideline2026_Alaska":{"persons":[19950,27050,34150,41250,48350,55450,62550,69650],"perExtraAfter8":7100}}}
{"sponsor":"AstraZeneca","url":"https://www.azandmeapp.com/included-medications","readDate":"2026-10-30","method":"chrome page text, product logo alt text and application links","facts":{"listedDrugs":["Airsupra","Baxfendy","Bevespi Aerosphere","Breztri Aerosphere","Lokelma","Calquence","Etcamah","Fasenra","Imfinzi","Imjudo","Lynparza","Saphnelo","Tagrisso","Truqap","Wainua"],"notListed":["Symbicort","Brilinta","Farxiga"],"note":"the page text holds no drug names; the 15 products are the logo alt text and the application PDF links"}}
{"sponsor":"AbbVie","url":"https://www.abbvie.com/patients/patient-support/patient-assistance/available-programs.html","readDate":"2026-10-30","method":"chrome page text","facts":{"entries":96,"listedIncludes":["Humira","Skyrizi","Rinvoq","Venclexta","Imbruvica","Lupron Depot","Mavyret"],"notListed":["Viekira Pak"],"note":"full available-medicines list under the myAbbVie Assist program; v1.0 had read only the returning-patient list on the program page"}}
{"sponsor":"GSK","url":"https://gskpaf.org/gsk/faqs/","readDate":"2026-10-30","method":"chrome page text","facts":{"incomeFigureUninsuredPath":"not stated","note":"the program page and FAQ say only that applicants must meet financial income eligibility criteria; no dollar or percentage figure for the uninsured path"}}